Results 131 to 140 of about 498,238 (269)

Extramedullary Disease—Achilles Heel in Myeloma?

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion
Shaji Kumar   +7 more
wiley   +1 more source

185 The Youth is our Future, and the Future is Here

open access: yesResearch and Practice in Thrombosis and Haemostasis
Omkar Garud   +4 more
doaj   +1 more source

Deep Venous Thrombosis in COVID-19 Patients: A Cohort Analysis

open access: gold, 2020
Chuanqi Cai   +11 more
openalex   +1 more source

180 Elevation of D-Dimer Without Any Evidence of Venous Thromboembolism: What Is Your Interpretation?

open access: yesResearch and Practice in Thrombosis and Haemostasis
Om Joshi   +4 more
doaj   +1 more source

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy

open access: yesAmerican Journal of Hematology, EarlyView.
Early cardiac biomarker monitoring in AML induction therapy showed significantly higher hsTnT levels after daunorubicin 90 mg/m2 compared with 60 mg/m2, indicating a dose‐dependent early myocardial effect. ABSTRACT Anthracyclines are an essential component of induction therapy for acute myeloid leukemia (AML), but their optimal dosing and the ...
Stefan Markus Dendorfer   +44 more
wiley   +1 more source

Home - About - Disclaimer - Privacy